{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 21,
  "pageCount": 58,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "industry_trends",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "quote_block",
    "photo"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/21",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-21",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc0-647be729ec54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials by modality (2018-21)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "420b2557-24e5-4dec-b3c8-263aeb409f50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of newly started clinical trials: 124%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc0-6ce30e87e8fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.21
      },
      "kind": "quote",
      "text": "Market feedback",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9e0082a-c323-44e6-9cd9-019befea44e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Our company starts to focus on cell and gene-oriented therapies which we think would be the major modalities in the future, as traditional modalities could only provide marginal benefit for patients ... - R&D Lead, a leading MNC pharma, Sept. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc0-6a0addd133e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: DXY, L.E.K. interviews and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70acc078-6ca0-48b6-8865-b38045e464b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.95,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a589c923-1e84-4eb9-991f-3fd579d19d02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b771833c-53f8-43e7-94d3-fe6266a84aa8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of newly started clinical trials",
      "numberRaw": "124%",
      "numberKind": "percent",
      "actionTitle": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape",
      "calloutText": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape.",
      "numberScale": null,
      "numberValue": 124,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}